Niacin extended release (ER)/simvastatin (Simcor(R)): a guide to its use in lipid regulation.

Author(s): Lyseng-Williamson KA

Affiliation(s): Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz

Publication date & source: 2010, Drugs R D., 10(4):253-60.

Publication type: Review

Oral fixed-dose niacin extended release/simvastatin is associated with clinically relevant improvements in plasma lipid profiles, including lowering of non-high-density lipoprotein cholesterol levels, relative to simvastatin monotherapy in patients with mixed dyslipidemias who had not responded fully to simvastatin monotherapy, and is generally well tolerated.